David Clements

David has over 25 years of experience in molecular biology and the development of recombinant protein expression systems at Hawaii Biotech. He has worked on a variety of projects involving molecular genetics and has extensive experience in the expression of recombinant proteins in heterologous host cell systems. He has been actively involved in the development of Hawaii Biotech’s recombinant subunit vaccine platform, utilizing a stable insect cell expression system. For the past 15 years, He has been responsible for the development of the necessary cell lines and large-scale cell culture processes needed for cGMP production of the dengue and West Nile virus vaccines. This includes production of pilot lots suitable for toxicology studies, tech-transfer to GMP manufactures and oversite of upstream and downstream operations. In addition to his role in cGMP manufacture, he has also have been involved in the preparation of pre-IND and IND packages for the dengue, West Nile and Zika vaccines. He has been Principle Investigator on several SBIR grants directed towards the development of recombinant subunit vaccines for malaria, Tick-borne flaviviruses, Crimean-Congo hemorrhagic fever, Chikungunya, and SARS 1 and 2. He received his degree in Biochemistry from the University of Hawaii at Manoa, where his studies focused on the molecular genetics of toxin production in plant pathogenic bacteria.